Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials. Issue 5 (May 2021)

• Record Type: Journal Article
• Authors: Zhang, Zeyi; Chen, Ou
• Is Part Of: Journal of cardiovascular pharmacology. Volume 77:Issue 5(2021)
• Publication Date: 2021-05
• Subjects: ticagrelor -- P2Y12 inhibitors -- percutaneous coronary intervention -- diabetes; Cardiovascular Diseases -- drug therapy -- Periodicals; Cardiovascular System -- drug effects -- Periodicals; Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular agents; Cardiovascular pharmacology; Periodicals; 615.7105
• DOI: 10.1097/FJC.0000000000000995
• Languages: English
• ISSNs: 0160-2446

Abstract

Abstract : Abstract: Dual antiplatelet treatment, consisting of aspirin and P2Y12 inhibitors, is essential for diabetes mellitus (DM) patients who have undergone percutaneous coronary intervention (PCI). This meta-analysis investigated whether ticagrelor, a novel P2Y12 inhibitor, was superior to clopidogrel and prasugrel in efficacy and safety for DM patients undergoing PCI. PubMed, the Cochrane Library and Google Scholar were searched for randomized controlled trials in which ticagrelor was administered. Eligible studies were independently scrutinized to extract data and assess the trials' quality. Statistical analysis was performed by calculating odds ratios (OR) and 95% confidence intervals (CI). A total of 8 studies consisting of 1056 patients were included. Results showed that ticagrelor reduced the major adverse cardiac events incidence compared with clopidogrel and prasugrel in the overall (OR = 0.40; 95% CI, 0.20–0.79; P = 0.008) and subgroup analyses compared with clopidogrel (OR = 0.39; 95% CI, 0.19–0.80; P = 0.01). No difference was observed in mortality rates (OR = 0.58; 95% CI, 0.23–1.45; P = 0.25), myocardial infarction (OR = 0.67; 95% CI, 0.28–1.60; P = 0.37), stroke (OR = 0.54; 95% CI, 0.10–3.01; P = 0.49), and total bleeding (OR = 1.70; 95% CI, 0.91–3.17; P = 0.10) between the ticagrelor and control groups. In DM patients undergoing PCI, ticagrelor significantly reduced major adverse cardiac events compared with clopidogrel and prasugrel in the overall and in the subgroup of clopidogrel. There was no difference regarding mortality, myocardial infarction, stroke, and bleeding. More randomized controlled trials are required to further validate these results.